Skip to main content
Clinical Trials/CTRI/2024/02/063349
CTRI/2024/02/063349
Not yet recruiting
Phase 4

A Randomized Comparative Study to Evaluate The Effects and Safety of Intrathecal Hyperbaric Levobupivacaine 0.5% and Hyperbaric Ropivacaine 0.75% In Patients Undergoing Transurethral Resection of Prostate(TURP) Surgery under Spinal Anaesthesia

Karan Malhotra1 site in 1 country50 target enrollmentStarted: March 1, 2024Last updated:

Overview

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Karan Malhotra
Enrollment
50
Locations
1
Primary Endpoint
The objective of the study is to evaluate the efficacy in terms of onset and duration of sensory block as primary outcome in two groups: Group 1(L) – 3ml 0.5% hyperbaric levobupivacaine and Group 2(R) – 3ml 0.75% hyperbaric ropivacaine.

Overview

Brief Summary

The present prospective, randomized and double blind study will be conducted in Department of Anaesthesiology, MMIMSR Mullana Ambala, Haryana. After the approval of protocol by the Institutional Ethics Committee, and registration with Clinical Trial Registry India, a total number of 50 ASA I and ASA II status patients scheduled for elective TURP surgery under spinal anaesthesia will be included in the study after obtaining informed consent for the study. The effects and efficacy of hyperbaric LEVOBUPIVACAINE 0.5% and hyperbaric ROPIVACAINE 0.75% will be compared.

Study Design

Study Type
Interventional
Allocation
Na
Masking
Participant and Investigator Blinded

Eligibility Criteria

Ages
0.00 Year(s) to 99.00 Year(s) (—)
Sex
Male

Inclusion Criteria

  • ASA 1 and ASA 2 patients posted for TURP.

Exclusion Criteria

  • Negative consent by the patient
  • Contraindication for spinal Anaesthesia (such as coagulopathy, infection at injection site, hypotension, disease or deformity of spine)
  • Psychiatric patient
  • ASA status III/IV
  • Known sensitivity to the drug.

Outcomes

Primary Outcomes

The objective of the study is to evaluate the efficacy in terms of onset and duration of sensory block as primary outcome in two groups: Group 1(L) – 3ml 0.5% hyperbaric levobupivacaine and Group 2(R) – 3ml 0.75% hyperbaric ropivacaine.

Time Frame: Outcomes will be assessed at baseline, time intervals of 2min upto 10min after administration of spinal anaesthesia with the selected drugs followed by every 5 minutes until completion of surgery

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Karan Malhotra
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Karan Malhotra

MMIMSR, Mullana

Study Sites (1)

Loading locations...

Similar Trials